SCHEMBL7429374

SCHEMBL7429374

COC(=O)C=Cc1ccc(-c2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.63
EPHX2 P34913 1/20 0.60
NFE2L2 Q16236 1/20 0.59
ABCG2 Q9UNQ0 5/20 0.57
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
TYR P14679 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
MAPK1 P28482 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MAPT P10636 2/20 0.55
JAK2 O60674 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL2411955 0.87 FDPS (0.80) FDPSEPHX2NFE2L2ABCG2KDM4E
Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL2411956 0.87 FDPS (0.80) FDPSEPHX2NFE2L2ABCG2KDM4E
SCHEMBL7967589 0.86 KDM4E (0.77) NFE2L2ABCG2CA12CA1CA2
SCHEMBL7967595 0.86 KDM4E (0.77) NFE2L2ABCG2CA12CA1CA2
SCHEMBL8267192 0.81 HDAC8 (0.73) CA12CA1CA2TYRCA7
Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL7524794 0.80 KDM4E (0.76) FDPSEPHX2NFE2L2ABCG2CA12
SCHEMBL71224 0.80 CA12 (0.84) FDPSEPHX2NFE2L2CA12CA1
SCHEMBL5057418 0.80 CA12 (0.84) FDPSEPHX2NFE2L2CA12CA1
SCHEMBL15599441 0.80 KDM4E (0.48) FDPSEPHX2NFE2L2KDM4EALDH1A1
SCHEMBL15599425 0.80 KDM4E (0.48) FDPSEPHX2NFE2L2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235793-A2 VLA-4 INTEGRIN ANTAGONISTS Novartis AG (CH) 2002-09-04 EP disclosed
WO-2001042192-A2 VLA-4 INTEGRIN ANTAGONISTS NOVARTIS AG (CH) 2001-06-14 WO disclosed